Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Prabhjot Kaur Juttla, Boniface Mwangi Chege, Peter Waweru Mwangi & Frederick Bukachi. (2024) Dapagliflozin Pretreatment Prevents Cardiac Electrophysiological Changes in a Diet and Streptozotocin Induction of Type 2 Diabetes in Rats: A Potential New First-Line?. Journal of Experimental Pharmacology 16, pages 123-133.
Read now
Read now
Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis & John Parissis. (2023) Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology 16:2, pages 149-160.
Read now
Read now
Bharat Narasimhan, R. Aravinthkumar, Ashish Correa & Wilbert S. Aronow. (2021) Pharmacotherapeutic principles of fluid management in heart failure. Expert Opinion on Pharmacotherapy 22:5, pages 595-610.
Read now
Read now
Na Li & Hong Zhou. (2020) SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy. Drug Design, Development and Therapy 14, pages 4775-4788.
Read now
Read now
Ioanna Papakitsou, George Vougiouklakis, Moses S Elisaf & Theodosios D Filippatos. (2019) Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical Pharmacology: Advances and Applications 11, pages 133-143.
Read now
Read now
Rosemarie Lajara. (2019) Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine 131:8, pages 555-565.
Read now
Read now
Articles from other publishers (67)
Emanuel Tenório Paulino. (2024) Development of the cardioprotective drugs class based on pathophysiology of myocardial infarction: A comprehensive review. Current Problems in Cardiology 49:5, pages 102480.
Crossref
Crossref
Michal Krčma. (2024) Metabolic effects of glyphlozines. Vnitřní lékařství 70:2, pages 91-96.
Crossref
Crossref
Jacob Epperson, Zoraize Moeez Athar, Mahnoor Arshad & Edward Chen. (2024) A Review of Sodium-Glucose Cotransporter 2 Inhibitor’s Clinical Efficacy in Heart Failure With Preserved Ejection Fraction. Cureus.
Crossref
Crossref
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, Deédeni Devos, Juan D. Salazar, Víctor M. Víctor & Susana Rovira-Llopis. (2024) Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress. Free Radical Biology and Medicine 213, pages 19-35.
Crossref
Crossref
Sul A. Lee & Leonardo V. Riella. (2024) Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers. Kidney International Reports.
Crossref
Crossref
Sumel Ashique, Neeraj Mishra, Ashish Garg, Sweta Garg, Arshad Farid, Shweta Rai, Gaurav Gupta, Dua Kamal, Keshav Raj Paudel & Farzad Taghizadeh-Hesary. (2024) A Critical Review on the Long-term COVID-19 Impacts on Patients with Diabetes. The American Journal of Medicine.
Crossref
Crossref
Yi-Hsuan Lin, Chia-Hung Lin, Yu-Chih Lin, Yu-Yao Huang, An-Shun Tai, Shih-Chen Fu & Sheng-Hsuan Lin. (2024) Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study. Endocrine Practice.
Crossref
Crossref
Vennela Avula, Garima Sharma, Mikhail N. Kosiborod, Muthiah Vaduganathan, Tomas G. Neilan, Teresa Lopez, Susan Dent, Lauren Baldassarre, Marielle Scherrer-Crosbie, Ana Barac, Jennifer Liu, Anita Deswal, Sumanth Khadke, Eric H. Yang, Bonnie Ky, Daniel Lenihan, Anju Nohria, Sourbha S. Dani & Sarju Ganatra. (2024) SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC: Heart Failure 12:1, pages 67-78.
Crossref
Crossref
Mohammad Hadi Mansouri, Pejman Mansouri, Masoumeh Sadeghi, Seyedeh Melika Hashemi, Alireza Khosravi, Mohaddeseh Behjati, Javad Shahabi, Asieh Mansouri, Reihaneh Zavar, Afshin Amirpour, Hamid Sanei & Nizal Sarrafzadegan. (2023) Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double‐blind placebo‐controlled trial (EMPT‐ANGINA Trial). Clinical Cardiology 47:1.
Crossref
Crossref
Sumit Saha, Xianjun Fang, Christopher D. Green & Anindita Das. (2023) mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy. International Journal of Molecular Sciences 24:20, pages 15078.
Crossref
Crossref
Ajinath Kale, Anshima Sharma, Hans-Joachim Anders & Anil Bhanudas Gaikwad. (2023) Diabetes and Cardiorenal Complications: A Clinical Review of Existing
Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors. Current Diabetes Reviews 19:8.
Crossref
Crossref
Eren IMRE, Hatice G. GUNHAN, Pinar EREL & Ozlem USTAY. (2023) SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real-world retrospective observational study. Minerva Endocrinology 48:3.
Crossref
Crossref
Djordje S. Popovic, Nikolaos Papanas, Theocharis Koufakis, Kalliopi Kotsa, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Alberto Firenze, Massimo Galia, Su-Yen Goh, Andrej Janez, Sanjay Kalra, Peter Kempler, Nitin Kapoor, Nader Lessan, Paulo Lotufo, Ali A. Rizvi, Amirhossein Sahebkar, Raul D. Santos, Anca Pantea Stoian, Peter P. Toth, Vijay Viswanathan & Manfredi Rizzo. (2023) Glucometabolic Perturbations in Type 2 Diabetes Mellitus and
Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using
Novel Antidiabetic Drugs – The CAPISCO International Expert
Panel. Experimental and Clinical Endocrinology & Diabetes 131:05, pages 260-267.
Crossref
Crossref
Nilanjan Ghosh, Leena Chacko, Hiranmoy Bhattacharya, Jayalakshmi Vallamkondu, Sagnik Nag, Abhijit Dey, Tanushree Karmakar, P. Hemachandra Reddy, Ramesh Kandimalla & Saikat Dewanjee. (2023) Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies. Biomedicines 11:4, pages 1126.
Crossref
Crossref
Jacob E. Pruett, Damian G. Romero & Licy L. Yanes Cardozo. (2023) Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. Frontiers in Endocrinology 14.
Crossref
Crossref
Y.A. El-Taravi, D. V. Baimukhambetova, C. L. Gorlenko, H. Yu. Kiseljow, I. Iu. Kokhanovskaia, A. I. Burotina, E. S. Rassadina, N. S. Martirosian & N. A. Petunina. (2023) Management of diabetes during Ramadan: an update for Russian-speaking doctors. Diabetes mellitus 26:1, pages 82-92.
Crossref
Crossref
Yuliya Fedorchenko & Olena Zimba. (2023) Comorbidities in the COVID-19 Pandemic: Scopus-Based Bibliometric Analysis. Journal of Korean Medical Science 38:11.
Crossref
Crossref
Michele Correale, Pietro Mazzeo, Adriana Mallardi, Alessandra Leopizzi, Lucia Tricarico, Martino Fortunato, Michele Magnesa, Salvatore Tucci, Pasquale Maiellaro, Giuseppe Pastore, Olga Lamacchia, Massimo Iacoviello, Matteo Di Biase & Natale Daniele Brunetti. (2021) Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure. Cardiovascular Drugs and Therapy 36:6, pages 1157-1164.
Crossref
Crossref
Lei Tian, Sinan Ai, Huijuan zheng, Hanwen Yang, Mengqi Zhou, Jingyi Tang, Weijing Liu, Wenjing Zhao & Yaoxian Wang. (2022) Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Sumanth KHAKDE, Hafsa JAWAID, Farah YASMIN, Mashal BINTE ALI & Abdur REHMAN. (2022) Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinology 47:3.
Crossref
Crossref
Shailendra Singh Bhadauria, Rishabha Malviya & Pramod Kumar Sharma. (2022) Unwinding Link between Coronavirus and Diabetes Patient. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:11, pages 1091-1110.
Crossref
Crossref
Sencer Çamcı & Emre Yılmaz. (2022) Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. Medicina 58:8, pages 1128.
Crossref
Crossref
Jinchun Wu, Yanmin Liu, Xiaojuan Wei, Xiaofei Zhang, Yi Ye, Wei Li & Xiaoling Su. (2022) Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Suzanne N. Voorrips, Huitzilihuitl Saucedo-Orozco, Pablo I. Sánchez-Aguilera, Rudolf A. De Boer, Peter Van der Meer & B. Daan Westenbrink. (2022) Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. International Journal of Molecular Sciences 23:15, pages 8631.
Crossref
Crossref
Yousef Faridvand, Maryam Nemati, Elham Zamani-Gharehchamani, Hamid Reza Nejabati, Arezoo Rezaie Nezhad Zamani, Samira Nozari, Nasser Safaie, Mohammad Nouri & Ahmadreza Jodati. (2022) Dapagliflozin Protects H9c2 Cells Against Injury Induced by
Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB
Activity. Current Molecular Pharmacology 15:6, pages 862-869.
Crossref
Crossref
Stefano Michelassi. (2022) SGLT2 inhibitors: suggestions from the amphibian world. Giornale di Clinica Nefrologica e Dialisi 34, pages 63-69.
Crossref
Crossref
Huiting Xia, Aqeela Zahra, Meng Jia, Qun Wang, Yunfu Wang, Susan L. Campbell & Jianping Wu. (2022) Na+/H+ Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure. Pharmaceuticals 15:7, pages 875.
Crossref
Crossref
Nikolaos Karamichalakis, Andrew Xanthopoulos, Filippos Triposkiadis, Ioannis Paraskevaidis & Elias Tsougos. (2022) Reshaping Treatment of Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine 11:13, pages 3706.
Crossref
Crossref
Hani Essa, Lauren Walker & Rajiv Sankaranarayanan. (2021) Sodium‐glucose co‐transporter‐2 inhibitors in the non‐diabetic heart failure patient. British Journal of Clinical Pharmacology 88:6, pages 2566-2570.
Crossref
Crossref
Tomasz Gęca, Kamila Wojtowicz, Paweł Guzik & Tomasz Góra. (2022) Increased Risk of COVID-19 in Patients with Diabetes Mellitus—Current Challenges in Pathophysiology, Treatment and Prevention. International Journal of Environmental Research and Public Health 19:11, pages 6555.
Crossref
Crossref
Benjamin Burggraaf, Nadine M C Pouw, Salvador Fernández Arroyo, Leonie C van Vark-van der Zee, Gert-Jan M van de Geijn, Erwin Birnie, Jeannine Huisbrink, Ellen M van der Zwan, Wouter W de Herder, Monique T Mulder, Patrick C N Rensen & Manuel Castro Cabezas. (2022) Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus. European Journal of Endocrinology 186:5, pages 597-605.
Crossref
Crossref
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich & Vladimir Jakovljevic. (2021) SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Failure Reviews 27:3, pages 935-949.
Crossref
Crossref
Deepika Dasari, Audesh Bhat, Sureshbabu Mangali, Trupti Ghatage, Ganesh Panditrao Lahane, Dharmarajan Sriram & Arti Dhar. (2022) Canagliflozin and Dapagliflozin Attenuate Glucolipotoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1. ACS Pharmacology & Translational Science 5:4, pages 216-225.
Crossref
Crossref
Yi-Hsuan Lin, Chia-Hung Lin, Yu-Yao Huang, An-Shun Tai, Shih-Chen Fu, Szu-Tah Chen & Sheng-Hsuan Lin. (2022) Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study. Diabetes Research and Clinical Practice 186, pages 109816.
Crossref
Crossref
Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2022) Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022, pages 1-17.
Crossref
Crossref
Ara Aboolian, Sofia Urner, Michael Roden, Jay Chandra Jha & Karin Jandeleit-Dahm. 2022. From Obesity to Diabetes. From Obesity to Diabetes
269
307
.
Yuze Zhang, Xiaoyan Lin, Yong Chu, Xiaoming Chen, Heng Du, Hailin Zhang, Changsheng Xu, Hong Xie, Qinyun Ruan, Jinxiu Lin, Jie Liu, Jinzhang Zeng, Ke Ma & Dajun Chai. (2021) Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Djordje S. Popovic, Nikolaos Papanas, Anca Pantea Stoian, Ali A. Rizvi, Andrej Janez & Manfredi Rizzo. (2021) Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. Diabetes Therapy 12:12, pages 3037-3054.
Crossref
Crossref
Jiang Liu, Jiang Tian, Komal Sodhi & Joseph I. Shapiro. (2021) The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?. The Journal of Membrane Biology 254:5-6, pages 513-529.
Crossref
Crossref
Gloria M. Gager, Dirk von Lewinski, Harald Sourij, Bernd Jilma, Ceren Eyileten, Krzysztof Filipiak, Martin Hülsmann, Jacek Kubica, Marek Postula & Jolanta M. Siller-Matula. (2021) Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomedicine & Pharmacotherapy 143, pages 112169.
Crossref
Crossref
Dorit Samocha-Bonet, Buffy Wu & David K. Ryugo. (2021) Diabetes mellitus and hearing loss: A review. Ageing Research Reviews 71, pages 101423.
Crossref
Crossref
Soraya Puglisi, Alessandro Rossini, Roberta Poli, Francesca Dughera, Anna Pia, Massimo Terzolo & Giuseppe Reimondo. (2021) Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology 12.
Crossref
Crossref
José Silva-Cardoso, Aurora Andrade, Dulce Brito, Jorge Ferreira, Cândida Fonseca, Marisa Peres, Fátima Franco & Brenda Moura. (2021) SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa de Cardiologia (English Edition) 40:9, pages 687-693.
Crossref
Crossref
José Silva-Cardoso, Aurora Andrade, Dulce Brito, Jorge Ferreira, Cândida Fonseca, Marisa Peres, Fátima Franco & Brenda Moura. (2021) SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa de Cardiologia 40:9, pages 687-693.
Crossref
Crossref
Yakov F. Zverev & Anna Y. Rykunova. (2021) Direct cardial effects and mechanisms of cardiovascular action of gliflosins. Reviews on Clinical Pharmacology and Drug Therapy 19:2, pages 131-143.
Crossref
Crossref
Ya. F. Zverev & A. Ya. Rykunova. (2021) Nephroprotective effect of novel oral sugar-reducing medicines: glyflosins. Nephrology (Saint-Petersburg) 25:4, pages 11-22.
Crossref
Crossref
Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding & Stephen C. Bain. (2021) Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs 81:11, pages 1243-1255.
Crossref
Crossref
Jaime McDermott, Carolina Tennyson & Elizabeth Bell-McClure. (2021) Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block. The Journal for Nurse Practitioners 17:6, pages 652-656.
Crossref
Crossref
Jana Goerg, Manuela Sommerfeld, Bettina Greiner, Dilyara Lauer, Yasemin Seckin, Alexander Kulikov, Dmitry Ivkin, Ulrich Kintscher, Sergey Okovityi & Elena Kaschina. (2021) Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a. International Journal of Molecular Sciences 22:11, pages 5437.
Crossref
Crossref
Yakov F. Zverev & Anna Ya. Rykunova. (2021) Proposed mechanisms of systemic cardiovascular action of gliflosins. Reviews on Clinical Pharmacology and Drug Therapy 19:1, pages 5-22.
Crossref
Crossref
Vijay Viswanathan, Anudeep Puvvula, Ankush D Jamthikar, Luca Saba, Amer M Johri, Vasilios Kotsis, Narendra N Khanna, Surinder K Dhanjil, Misha Majhail, Durga Prasanna Misra, Vikas Agarwal, George D Kitas, Aditya M Sharma, Raghu Kolluri, Subbaram Naidu & Jasjit S Suri. (2021) Bidirectional link between diabetes mellitus and coronavirus disease 2019 leading to cardiovascular disease: A narrative review. World Journal of Diabetes 12:3, pages 215-237.
Crossref
Crossref
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu & Dingli Xu. (2021) Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Nikolaos C. Kyriakidis, Gabriela Cobo, Lu Dai, Bengt Lindholm & Peter Stenvinkel. (2021) Role of Uremic Toxins in Early Vascular Ageing and Calcification. Toxins 13:1, pages 26.
Crossref
Crossref
Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Giuseppe Bellastella, Carlo Garofalo, Paolo Chiodini, Antonio Ceriello & Katherine Esposito. (2020) Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovascular Diabetology 19:1.
Crossref
Crossref
M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser & M. Arad. (2020) Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Marina Makrecka-Kuka, Stanislava Korzh, Melita Videja, Karlis Vilks, Helena Cirule, Janis Kuka, Maija Dambrova & Edgars Liepinsh. (2020) Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload. Cardiovascular Drugs and Therapy 34:6, pages 791-797.
Crossref
Crossref
O.S. Voronenko, M.S. Brynza & I.M. Kolomytseva. (2020) Modern possibilities of pharmacotherapy in a patient with type 2 diabetes mellitus in combination with chronic heart failure. Experimental and Clinical Medicine 88:3, pages 21-29.
Crossref
Crossref
Melroy S. D'Souza, Tiffany A. Dong, Gabrielle Ragazzo, Devinder S. Dhindsa, Anurag Mehta, Pratik B. Sandesara, Andrew M. Freeman, Pam Taub & Laurence S. Sperling. (2020) From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease. The American Journal of Medicine 133:10, pages 1126-1134.
Crossref
Crossref
Alexander J M Brown, Stephen Gandy, Rory McCrimmon, John Graeme Houston, Allan D Struthers & Chim C Lang. (2020) A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. European Heart Journal 41:36, pages 3421-3432.
Crossref
Crossref
Cen Yan, Lutgarde ThijsYu Cao, Sander TrensonZhen-Yu ZhangStefan JanssensJan A. Staessen & Ying-Mei Feng. (2020) Opportunities of Antidiabetic Drugs in Cardiovascular Medicine. Hypertension 76:2, pages 420-431.
Crossref
Crossref
Ritesh Gupta, Akhtar Hussain & Anoop Misra. (2020) Diabetes and COVID-19: evidence, current status and unanswered research questions. European Journal of Clinical Nutrition 74:6, pages 864-870.
Crossref
Crossref
Gary D. Lopaschuk & Subodh Verma. (2020) Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. JACC: Basic to Translational Science 5:6, pages 632-644.
Crossref
Crossref
Rossella D’Oria, Rossella Schipani, Anna Leonardini, Annalisa Natalicchio, Sebastio Perrini, Angelo Cignarelli, Luigi Laviola & Francesco Giorgino. (2020) The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. Oxidative Medicine and Cellular Longevity 2020, pages 1-29.
Crossref
Crossref
Diogo Santos-Ferreira, Pedro Gonçalves-Teixeira & Ricardo Fontes-Carvalho. (2020) SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?. Cardiology 145:5, pages 311-320.
Crossref
Crossref
Jose Luis Górriz, Juan F Navarro-González, Alberto Ortiz, Ander Vergara, Julio Nuñez, Conxita Jacobs-Cachá, Alberto Martínez-Castelao & Maria Jose Soler. (2020) Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrology Dialysis Transplantation 35:Supplement_1, pages i13-i23.
Crossref
Crossref
Gaia Cattadori, Paola Pantanetti & Giuseppe Ambrosio. (2019) Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Research and Clinical Practice 157, pages 107835.
Crossref
Crossref
Niki Katsiki, Nikolaos Perakakis & Christos Mantzoros. (2019) Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism 98, pages iii-ix.
Crossref
Crossref